Dr. Joseph James Merchant, MD

Dr. Merchant practices at McFarland Clinic - 1215 Duff Avenue Office in Ames, Iowa.

Dr. Merchant's NPI, 1699765826, was assigned on October 27, 2005. Dr. Merchant graduated from University of Iowa, RJ & L Carver College of Medicine in 1993. Dr. Merchant holds Iowa license 31094.

Dr. Merchant's primary practice is McFarland Clinic - 1215 Duff Avenue Office, at 1215 Duff Ave, Ames, IA 50010. The practice phone is (515) 239-4436.

Dr. Merchant's primary practice is McFarland Clinic - 1215 Duff Avenue Office in Ames, Iowa. Dr. Merchant is also affiliated with Mary Greeley Medical Center. The medical group on file is McFarland Clinic. Dmand AI also links Dr. Merchant to 4 more hospitals, 2 hospices and 2 medical groups, each named with a free account. Dr. Merchant's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Merchant practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Merchant's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Merchant is licensed in Iowa.

CMS data shows 159,644 Medicare services from Dr. Merchant across 93 procedure codes in 2024, for 963 Medicare patients. Medicare paid $2,314,879 for them.

CMS counts 963 Medicare patients who saw Dr. Merchant in 2024. The largest group is 75 to 84, with 401 patients. 74% of them have high cholesterol, and 73% have high blood pressure. 4% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Merchant's median patient age at 70, with 59% women.

In 2024, Dr. Merchant wrote 5,210 Medicare Part D claims for 544 patients. 85% of them were for generic drugs. CMS names the drug for 4,691 of them, across 97 drugs with 11 or more claims each, at $4,384,946 in total drug cost. In 2023, CMS named 4,370 claims across 99 drugs.

Dr. Merchant accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Merchant to 10 clinical trials, 4 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 10.

CMS Open Payments shows 9 general payments to Dr. Merchant from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 50% of the total. Merck Sharp & Dohme Corporation paid the most, $232.

Dr. Merchant graduated from University of Iowa, RJ & L Carver College of Medicine in 1993.